论文部分内容阅读
为研究罗沙坦对高血压冠状动脉壁肥厚的逆转作用，将16 周大鼠分为自发性高血压大鼠(SHR)组、SHR 口服大剂量罗沙坦组[ 15mg/kg/d)]、SHR 口服小剂量罗沙坦组[0.75mg/kg.d)] 和正常血压大鼠(WKY)组，饲养10 周。结果显示大剂量罗沙坦治疗显著降低SHR 的收缩压，降低冠状动脉壁横截面积、横截面积与内径比，提高最大冠状动脉流量，小剂量罗沙坦治疗对SHR 的收缩压，外径>200 m m 冠状动脉壁横截面积、横截面积与内径比，及最大冠状动脉流量低下无影响，但能显著降低外径<200 m m 冠状动脉壁横截面积、横截面积与内径比。
In order to study the reversal effects of rosasartan on hypertensive coronary artery wall hypertrophy, 16-week-old rats were divided into spontaneously hypertensive rats (SHR) group and SHR high-dose losartan group [15mg / kg / d] , SHR oral low dose of losartan group [0.75mg / kg.d]) and normal blood pressure rats (WKY) group, feeding for 10 weeks. The results showed that high dose of losartan significantly reduced SHR systolic blood pressure, reduce the cross-sectional area of coronary artery wall, cross-sectional area and diameter ratio, increase the maximum coronary flow, low-dose rosumarin treatment SHR systolic blood pressure, > 200 mm coronary artery wall cross-sectional area, cross-sectional area and internal diameter ratio, and the maximum coronary artery flow was not affected, but can significantly reduce the diameter of <200 mm coronary artery wall cross-sectional area, cross-sectional area and diameter ratio.